Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 4,255,000 shares of common stock of Stemline Therapeutics, Inc. for approximately $59.6 million. The common stock is listed on the NASDAQ Global Select Market under the symbol “STML.”
Stemline is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers.
The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associates Ferrell Maguire Keel and Yoojin L. Kim. Associate Paul S. Lee provided intellectual property and technology advice. All members of the Davis Polk team are based in the New York office.